ST. LOUIS, Nov. 10, 2010 /PRNewswire-FirstCall/ — Stereotaxis,
Inc. (Nasdaq:
STXS) announced today that it intends, subject to market and
other conditions, to offer its common stock in a registered public
offering pursuant to its existing shelf registration statement
under the Securities Act of 1933. Stereotaxis also intends to grant
the underwriters of the offering an option to purchase additional
shares of common stock to cover over-allotments, if any.
Stereotaxis plans to use the proceeds from the offering for
sales, marketing, and clinical support initiatives, working
capital, continued research and development, and general corporate
purposes.
Oppenheimer & Co. Inc. is acting as sole book-running
manager for the offering.
Stereotaxis has filed a registration statement, as well as a
prospectus supplement and an accompanying prospectus, with the
Securities and Exchange Commission (SEC) in connection with the
offering. The prospectus supplement and accompanying prospectus may
be obtained by sending a request to Oppenheimer & Co. Inc.,
Attention: Syndicate Prospectus Department, 300 Madison Avenue, 5th
Floor, New York, NY, 10017, Telephone number: (212) 667-8563,
Email:
EquityProspectus@opco.com. Before you invest, you should read
the prospectus supplement and accompanying prospectus, the
registration statement, and the other documents that the Company
has filed with the Securities and Exchange Commission for more
complete information about the Company and this offering. Investors
may obtain these documents for free by visiting the SEC’s website
at www.sec.gov.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation
‘/>”/>
